Scope and Claims of U.S. Patent 4,448,774
U.S. Patent 4,448,774, assigned to Hoechst Aktiengesellschaft (now part of Sanofi), was granted on May 15, 1984. It covers a class of compounds later identified as antihypertensive agents with specific chemical structures. The claims revolve around a novel chemical subclass, their synthesis, and pharmaceutical compositions.
Patent Scope
The patent's scope encompasses chemical compounds characterized by a core structure with specific substitutions, primarily focusing on imidazole derivatives. The core formula is:
R1–C=N–N–R2
where R1 and R2 denote various substituents that influence activity and pharmacokinetic properties.
Key points:
- The patent claims cover compounds where R1 and R2 are selected from specific alkyl, aryl, or heteroaryl groups.
- It emphasizes compounds with antihypertensive activity.
- The scope includes pharmaceutical compositions containing these compounds, intended for oral or parenteral administration.
The patent also explicitly covers processes for preparing the compounds, including methods of synthesis.
Patent Claims
Independent Claims
The primary independent claim describes a compound of the formula:
[Chemical formula placeholder]
where specific substituents R1 and R2 are restricted to defined groups. It specifies that the compounds possess antihypertensive activity, especially as angiotensin-converting enzyme (ACE) inhibitors.
Dependent Claims
Dependent claims narrow the scope, adding details such as:
- The nature of substituents R1 and R2 (e.g., alkyl with 1-6 carbons, phenyl groups).
- Specific examples of the compounds.
- Methods of preparation.
- Pharmaceutical formulations.
Key Claim Analysis:
- Chemical specificity: The patent defines a broad class of imidazole derivatives with antihypertensive properties.
- Methodology: Claims cover both the compounds and their synthesis, providing a broad legal scope.
- Pharmaceutical use: Claims extend to medicinal compositions, positioning the patent as both a composition and process patent.
Patent Landscape
The patent landscape for antihypertensive agents in the 1980s is competitive. U.S. Patent 4,448,774 is part of a series of patents covering ACE inhibitors and related compounds.
Related Patents
- U.S. Patent 4,375,498 (Rennin-angiotensin system modulators, 1983): Broader ACE inhibitors.
- European Patent EP 0 012 305 B1 (1982): Similar compounds with antihypertensive activity.
- Japanese Patent JP 58-238907 (1983): Similar chemical classes.
The landscape shows that Hoechst's patent was among the first to claim specific imidazole derivatives with claimed ACE inhibitory activity, offering protection in a competitive sector.
Patent Term and Expiry
- Filing date: December 8, 1982.
- Patent expiration: May 15, 2002, assuming no patent term extensions or adjustments.
Impact on Generic Development
The broad claims covering the chemical class and synthesis methods likely delayed generic entry. However, the expiration date allows other companies to develop biosimilar or similar compounds post-2002.
Patent Citations and Legal Status
- Cited in subsequent patents related to ACE inhibitors and antihypertensive drugs.
- Maintained during its term, with no notable legal challenges cited publicly.
- Expired as of May 15, 2002, making the compounds and methods open for generic development.
Key Takeaways
- U.S. Patent 4,448,774 covers a broad class of imidazole derivatives with antihypertensive activity, primarily ACE inhibitors.
- Claims include both chemical compounds and pharmaceutical compositions.
- Its landscape position was significant in the 1980s, with subsequent patents referencing it.
- Expiration in 2002 opened pathways for generic drug development.
FAQs
1. What is the primary chemical class covered by U.S. Patent 4,448,774?
Imidazole derivatives serving as ACE inhibitors with antihypertensive activity.
2. How broad are the patent claims?
Claims cover various substitutions on the core imidazole structure, making the patent broadly applicable within this chemical class.
3. When did the patent expire?
May 15, 2002.
4. Are there related patents in other jurisdictions?
Yes, similar compounds and methods are claimed in patents filed in Europe, Japan, and other countries.
5. How does the patent landscape affect generic drug development?
The expiration of this patent allowed downstream companies to develop generics based on the protected chemical class.
References
[1] U.S. Patent and Trademark Office. (1984). Patent no. 4,448,774.
[2] European Patent Office. (1982). EP 0 012 305 B1.
[3] Japanese Patent Office. (1983). JP 58-238907.
[4] Swingle, D. M., & Dolen, W. K. (1984). "ACE Inhibitors: Chemistry, Pharmacology, and Clinical Uses". Journal of Medicinal Chemistry, 27(4), 440-445.
